Clinical evaluation of Simhanada guggulu in Amavata.

Pharmaceutico-Analytical & Clinical study of Simhnada guggulu prepared by different methods in Amavata

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/07/034755

Enrollment

Registered

2021-07-12

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M259- Joint disorder, unspecified

Interventions

Intervention1: Simhanada guggulu Avaleha: Group A will be given Simhanada guggulu 1 gm each in Avaleha form thrice a day anupan of lukewarm water for 28 days Control Intervention1: Simhanada Guggulu T

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients willing to participate in the trial. 2) Patients between the age group of 18-70 years of age. 3) Patient having signs and symptoms of Amavata. 4) Patients fulfilling the criteria for diagnosis of Rheumatoid arthritis approved by ARA 2000 revision.

Exclusion criteria

Exclusion criteria: 1) Patients under long-term steroids and cytotoxic treatments. 2) Patients having complications including contractures, nodules, etc. 3) Patients with a concomitant illness like HTN, DM. 4) Patients with evidence of malignancy. 5) Pregnant or lactating females

Design outcomes

Primary

Measure	Time frame
Improvement in joint pain.Timepoint: 0th day 28th day	—

Secondary

Measure	Time frame
Improvement in pain, swelling and morning stiffness.Timepoint: 0th day 28th day	—

Countries

India

Contacts

Public ContactDr Deepmala Kumawat

National Institute of ayurveda

raj147sharma@gmail.com9414401151

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026